The MICs are working in collaboration with industry and academics to develop innovative approaches to generating evaluation evidence.

The IVD industry needs to be able to bring products to market more quickly than is typical for pharmaceutical products.  Innovation cycles are usually shorter, companies do not usually have the budget required for full randomised controlled trials (RCTs), and investors seek return on investment in a relatively short period of time.

The four MICs are collaborating to research and develop new methods to generate the evaluation evidence required by regulators and NHS commissioners in a more effective manner.